A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

The study ties first-trimester Oropouche infection to severe fetal neurodevelopmental anomalies and urges RT-PCR within 2-7 ...

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported ...